Acute Lymphoblastic Leukemia/Acute Myeloid Leukemia

Most of the research suggests combination therapies might be the best option for many patients who have acute myeloid leukemia (AML).

The study may help explain why some patients are more prone to relapse following a complete response to induction therapy, as indicated by measurable residual disease (MRD) status and 2017 European LeukemiaNet (ELN) criteria.

The findings suggest patient-reported outcomes—namely fatigue—may be helpful in identifying patients at a higher risk of death and other adverse outcomes but warrant further research.

Selected coverage of acute lymphoblastic leukemia (ALL) from the 65th American Society of Hematology Annual Meeting and Exposition, December 9-12 2023, San Diego, California.

Those with chronic graft-versus-host-disease who have received allogeneic hematopoietic stem cell transplant (alloHSCT) may experience enhanced graft-versus-leukemia effects, thus producing a lower relapse rate in acute myeloid leukemia.

Treatment with blinatumomab or inotuzumab ozogamicin particularly confers higher total costs for patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

A study evaluating disparities among children with acute leukemia found that Black children are more likely to present with higher disease burden at diagnosis compared with non-Hispanic White children.

Elevated white blood cell counts also appear to correlate with shorter overall survival in patients receiving standard induction chemotherapy plus cytarabine for acute myeloid leukemia.

A study found acute myeloid leukemia (AML) salvage therapy was independently associated with early mortality compared with frontline therapy, suggesting that algorithms measuring quality of care should incorporate risk mortality indices that factor in disease characteristics and treatment status.

A study highlights an unmet need for patients with acute myeloid leukemia (AML) to access and afford genomic testing, especially among an older patient population.